Omada Health, Inc. OMDA
At closeNov 3, 2026, 4:27 PM EST
After hours · Nov 3, 4:27 PM ET
- YTD
- +17.74%
- 1 year
- -27.62%
- Market cap
- 1.14B
- Revenue (ttm)
- 309.76M
- Profit margin
- 1.39%
- EPS (ttm)
- 0.24
- Shares out
- 61.22M
- P/E ratio
- 77.42
- Forward P/E
- 33.41
- YTD return
- +17.74%
- 1-year return
- -27.62%
- Volume
- 927.03K
- Avg volume
- 1.32M
- Open
- 17.92
- Previous close
- 17.85
- Day's range
- 17.92 – 18.76
- 52-week range
- 10.28 – 25.61
- Analysts
- Buy
- Price target
- 28.17 (+51.6%)
- Earnings date
- Nov 5, 2026
5D -1.42 (-7.37%)
Key statistics
- Enterprise value
- 871.01M
- PEG ratio
- 0.00
- Price / sales
- 3.67
- Price / book
- 4.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 43.10%
- Free cash flow
- 11.92M
- Total cash
- 221.71M
- Total debt
- 0
- Return on equity
- 1.84%
- Short % of float
- 13.89%
- 50-day average
- 20.63
- 200-day average
- 17.70
Analyst view
Consensus: buy
- Target (low)
- 22.00
- Target (mean)
- 28.17
- Target (high)
- 35.00
- Strong buy5
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.0981.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.06939 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.0622 | 0.15 | +0.09 | +141.16% |
| May 7, 2026 | Mar 31, 2026 | -0.08 | 0.01 | +0.09 | +112.50% |
| Mar 5, 2026 | Dec 31, 2025 | 0.03 | 0.13 | +0.10 | +333.33% |
| Nov 6, 2025 | Sep 30, 2025 | -0.10 | -0.06 | +0.04 | +40.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.10 | -0.09 | +0.01 | +10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Barclays | main | Overweight | Overweight |
| Oct 14, 2026 | Freedom Capital Markets | main | Buy | Buy |
| Sep 14, 2026 | Freedom Capital Markets | main | Buy | Buy |
| Sep 11, 2026 | Barclays | main | Overweight | Overweight |
| Sep 11, 2026 | Needham | reit | Buy | Buy |
| Sep 11, 2026 | BTIG | reit | Buy | Buy |
About Omada Health, Inc.
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- omadahealth.com
News
Barclays Maintains Overweight on Omada Health, Lowers Price Target to $24
Omada Health To Present Published Research Showing That Members Of Its GLP-1 Care Track Lost More Weight And Experienced Greater Improvements In Body Composition Than GLP-1 Users Receiving Usual Care
Omada Health to Present Peer-Reviewed Research on Improving Weight Loss and Body Composition During GLP-1 Treatment at World Obesity and Weight Management Congress
Omada Health to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 5, 2026
Transcript: Omada Health Q2 2026 Earnings Conference Call
Reviewing HCA Healthcare (NYSE:HCA) & Omada Health (NASDAQ:OMDA)
Omada Health, Inc. (NASDAQ:OMDA) Stock Has Average Price Target of $26.67
Bank of America Corp DE Acquires 313,440 Shares of Omada Health, Inc. $OMDA
Omada Health (NASDAQ:OMDA) and NeoGenomics (NASDAQ:NEO) Head-To-Head Contrast
Omada Health President Wei-Li Shao Sells 9,418 Shares for $236,000
Your note
Sign in to keep a note on OMDA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEAL ANNE | Director | Stock Award(Grant) | Jun 15, 2026 | 20,618 |
| COOK STEVEN L. | Chief Financial Officer | Sale | Sep 9, 2026 | 173,906 |
| DUFFY SEAN P | Chief Executive Officer | Sale | Sep 30, 2026 | 1,234,250 |
| FETTER TREVOR | Director | Stock Award(Grant) | Jul 1, 2026 | 135,621 |
| HILLEMAN JERYL L | Director | Stock Award(Grant) | Jul 1, 2026 | 26,519 |
| JAIN SACHIN H. | Director | Stock Award(Grant) | Jun 15, 2026 | 20,618 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Divisadero Street Capital Management, LP | 6.21% | 3,799,695 | 70.60M | Jun 29, 2026 |
| American Century Companies Inc | 6.01% | 3,678,676 | 68.35M | Jun 29, 2026 |
| Cigna Investments Inc/New | 5.63% | 3,444,629 | 64.00M | Sep 29, 2026 |
| Morgan Stanley | 4.58% | 2,800,887 | 52.04M | Jun 29, 2026 |
| FMR, LLC | 4.53% | 2,775,102 | 51.56M | Jun 29, 2026 |
| NVP Associates, LLC | 4.13% | 2,531,000 | 47.03M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 4.60% | 2,814,454 | 52.29M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.90% | 1,776,051 | 33.00M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.02% | 1,233,544 | 22.92M | Sep 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.65% | 1,012,400 | 18.81M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.65% | 1,007,298 | 18.72M | Aug 30, 2026 |
| LOOMIS SAYLES FUNDS II-Loomis Sayles Small Cap Growth Fund | 1.41% | 865,078 | 16.07M | Jun 29, 2026 |
